University of Richmond

Free "Asthma Equity Explorer" database maps asthma prevalence and risk factors in U.S. communities FAIRFAX, Va. and MCLEAN, Va., Feb. 1, 2024 /PRNewswire/ -- Allergy & Asthma Network and MITRE today announced the launch of the Asthma Equity Explorer™ at AsthmaEquity.org, a free web-based platform designed to disseminate data on asthma prevalence in the United States. With more than 25 million people in the United States living with asthma, the new tool enables families and health researchers to analyze data on asthma prevalence and related social determinants of health in communities nationwide. For example, users of the database can visualize and evaluate data, including socioeconomic factors, particulate matter concentration, and related asthma health measures at state, county, and city-levels. "We are excited to launch this database in partnership with MITRE," said Lynda Mitchell, CEO of Allergy & Asthma Network. "Asthma researchers and health professionals can go beyond asthma prevalence statistics to consider factors that lead to ongoing asthma disparities. It's an opportunity to bridge the gap and inform how social determinants of health impact asthma outcomes." The technology underpinning the new Asthma Equity Explorer was developed via MITRE's Independent Research and Development Program. Within the area of health, the not-for-profit's researchers are focused on pursuing evidence-based solutions that advance data interoperability and improve healthcare access and equity. Over the last 15 years, MITRE has issued nearly 1,800 licenses via its Technology Transfer Program impacting cybersecurity, national security, aviation safety, and health – including licensing this technology to Allergy & Asthma Network. "Partnering with Allergy & Asthma Network on this platform in the public interest is an example of how our Independent Research and Development Program allows us to prototype and develop market-ready solutions to real-world problems," said Charles Clancy, senior vice president and chief technology officer, MITRE. "The Asthma Equity Explorer will give researchers, public health officials, and healthcare providers the ability to uncover various risk factors and social determinants of health that contribute to the prevalence of the disease. This community-level data could also help families make significant lifestyle decisions – such as choosing where to live or attend school." Social determinants of health (SDOH) – the conditions of the places in which people live, work, learn, worship, and play – impact community-level asthma outcomes. The Asthma Equity Explorer applies health equity research to help inform community-based asthma interventions within their unique SDOH landscapes. By sourcing and combining data from Census.gov, Centers for Disease Control and Prevention, Atmospheric Composition Analysis Group, U.S. Department of Housing and Urban Development, U.S. Department of Agriculture, and University of Richmond, users of the Explorer can chart asthma prevalence using up to 32 different variables, including: Race/ethnicity Income to poverty ratio Education levels Home ownership vs. rental Access to healthy foods Affordable housing Smoking prevalence Obesity prevalence The Asthma Equity Explorer Database is for research purposes only and does not provide healthcare information, advice, diagnosis, or treatment. Use of the database requires free registration to allow for easy login for continued database analyses. All registration data will be kept private. Visit AsthmaEquity.org to learn more. About Allergy & Asthma Network Founded in 1985, Allergy & Asthma Network is the leading nonprofit outreach, education, advocacy and research organization for individuals and families living with allergies, asthma, and related conditions. Our mission is simple yet profound: to end needless death and suffering, empower people to take control of their health and well-being, and make healthcare more inclusive, equitable, and accessible for people living with these conditions. We are committed to raising awareness, promoting understanding, offering resources, fostering collaboration, and advocating for policies and research that enhance the quality of life for everyone impacted by these conditions. We specialize in making medically accurate information understandable to all while promoting evidence-based care. About MITRE MITRE's mission-driven teams are dedicated to solving problems for a safer world. Through our public-private partnerships and federally funded R&D centers, we work across government and in partnership with industry to tackle challenges to the safety, stability, and well-being of our nation. Learn more about MITRE's impact here. Contacts: Gary Fitzgerald Allergy & Asthma Network [email protected] Mike Murphy MITRE [email protected] SOURCE Allergy & Asthma Network

Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent. Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of large pharma and biotech experience and a track record of multiple high-value transactions in oncology and immuno-oncology. After over 6 years as CFO, Ms. Elizabeth Williams has chosen to pursue another biotech opportunity. A search for her replacement is currently underway. Company strengthens the management team with the appointment of Delphine Davan, MSc, MBA, as VP of Investor Relations, Evelyn Pau, PhD, as VP of External Collaborations; promotion of Eamonn Peters, CPA, CA to VP of Finance and Minh To, PhD, as VP of Oncology Research. TORONTO and HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today the appointment of Brent Meadows, MBA, as its Chief Business Officer (“CBO”), as part of the Company’s plans to establish a world-class C-suite in Boston, the industry’s largest biotech hub. Mr. Meadows brings over 25 years of business development, commercial strategy and marketing experience at large pharma and biotech companies, including Johnson & Johnson, Bristol-Myers Squibb, Shire/Baxalta, and Regeneron, among others. In this role, Mr. Meadows will be responsible for leadership of Medicenna’s business development and corporate strategy, including structuring, negotiating and executing key alliances and partnerships with Medicenna’s Phase 3 ready glioblastoma (“GBM”) asset, bizaxofusp, and its pipeline of clinical and pre-clinical Superkines. Medicenna's strategic decision to expand its leadership team in Boston represents a significant milestone in the company's growth trajectory. "On behalf of the Medicenna team, we are thrilled to welcome Brent as our CBO as we build our business development, financing and clinical leadership in Boston,” said Dr. Fahar Merchant, President and CEO of Medicenna. "Brent is an accomplished biopharma leader with an outstanding track record of multiple oncology transactions at both large pharma and biotech companies. By strengthening our executive team with additional C- level appointments in Boston, we look forward to an exciting phase this year and next as we anticipate to reach multiple value inflection milestones with MDNA11’s single-agent and combination dose expansion trials. Brent’s leadership will be key to ensuring that the full potential of bizaxofusp and our Superkine platforms are captured across therapy areas to bring transformative medicines to patients.” Mr. Meadows said, “I am very excited to join Medicenna’s team to build partnerships and execute transactions with its pipeline of highly differentiated clinical and pre-clinical Superkines, particularly its Phase 3 ready bizaxofusp, which has demonstrated encouraging results in patients with recurrent GBM, a devastating form of brain cancer. Medicenna is founded on transformational science, and I am looking forward to driving the Company's business development strategy as we execute our mission to bring these breakthroughs to more patients in need." Prior to joining Medicenna, Mr. Meadows served as CBO at OncoOne, where he defined the company's overall business strategy with his cross-functional leadership and oversaw business development, including deal execution. He has also held senior-level positions in business development, commercial strategy and marketing at Regeneron, Bristol Myers Squibb, Biogen and several senior positions at Johnson and Johnson. While at AVEO Oncology and Baxalta/Shire, he led or co-led multiple transactions, each worth over $1 billion. He has an MBA from Babson College and a BSc in Finance from University of Richmond. In addition, Medicenna is strengthening its investor relations and financial teams with the appointment of Delphine Davan as Vice President of Investor Relations and Communications, and the promotion of Eamonn Peters to Vice President of Finance. In supporting our partnerships with world-class academic groups and biopharma companies, Evelyn Pau joins the Company as VP of External Collaborations and Minh To is promoted to VP of Oncology Research to support the progression of early-stage immuno-oncology programs toward the clinic. The company also announces the departure of Elizabeth Williams, CPA, CA, from her role as Chief Financial Officer to pursue another biotech opportunity. “We thank Ms. Williams for her contribution to the Company since joining us in 2016 as CFO. We wish her the best of luck in her future endeavors.” said Dr. Merchant. “This marks a strategic turning point for Medicenna, as we bolster our team with professionals committed to the highest standards in corporate development, finance and effective investor interactions,” added Dr Merchant. Ms. Williams stated: “It has been an honor to be a part of the Medicenna team, and I look forward to following the future success of the Company.” About Medicenna Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Forward Looking Statements This news release contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company, plans and projections and other statements, including statements on the development and potential of the Superkines, on any potential benefits that may be realized as a result of new members of the management team, on its growth and business development, financing and clinical activities, the access to top-biotech talent, the Company’s corporate strategy and value inflection milestones with MDNA11’s single-agent and combination dose expansion trials. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially,” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest Annual Information Form and Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements. For further information about the Company please contact: Delphine Davan Vice President, Investor Relations and Corporate Communications, Medicenna Therapeutics Phone: 514-968-1046 ddavan@medicenna.com Media Contact For media inquiries, please contact: Tony Russo, Russo Partners, 212-845-4251, tony.russo@russopartnersllc.com

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva's US headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: (Photo: Business Wire) Dr. Grant joins Teva with over 25 years of experience in the global pharmaceutical and biotech industry, with an exceptional track record across a variety of fields including Business Development, R&D and Regulatory Affairs. Most recently, Dr. Grant served as the Chief Business Executive at BeiGene, overseeing business development, clinical and business insights and valuation, investments and collaborations, and alliance management. Before his tenure at BeiGene, Dr. Grant served as CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Earlier in his career, Dr. Grant spent 12 years at Celgene, serving in various leadership roles including Corporate Vice President of Business Development, and Vice President, Regulatory Affairs. Richard Francis, Teva’s President and CEO said: “We are pleased to welcome a leader of Angus caliber to our executive team at Teva. With a distinguished career spanning over more than two and a half decades in the global pharmaceutical and biotech industry, his breadth of experience and demonstrated expertise in business development, innovative R&D, and scientific affairs will be a significant asset to our organization. Mr. Francis continued: “These are exciting times at Teva, as we embark on our Pivot to Growth strategy, a crucial element of which involves amplifying our innovation through our already promising pipeline as well as fortifying our business development endeavors. I have full confidence in Angus leadership and firmly believe that he is exceptionally positioned to lead the business development efforts during this era of transformation. His contributions will be instrumental in driving external innovation, fostering collaborations across academia, biotech, and pharmaceutical sectors, and enhancing Teva's momentum in bringing innovative therapies to patients worldwide." Dr. Grant stated, "I am thrilled to be joining Teva's executive leadership team and am inspired by Teva's purpose and strategy to drive growth by stepping up and leaning more into innovation. I am looking forward to work with the extended Teva team and leading the excellent business development team, to drive innovation and to partner with the best minds in academia and the industry to bring meaningful impact and value for patients worldwide and for Teva." Angus Grant bio Angus has held executive leadership positions at BeiGene, a global, commercial-stage biotechnology company, where he led Strategy and Partnering. Angus also served as CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease and in senior leadership positions at Celgene. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham. After completing his PhD in Anatomy/ Immunology, Angus joined a clinical laboratory within the NIH prior to joining the FDA where he focused on cell and gene therapy IND processing. In 2006, Angus joined Celgene and held various leadership over his 12 years, including Corporate VP Business Development. Angus led deals ranging from R&D and commercialization collaborations to early equity investments, supply collaborations, M&A such as $9B Juno acquisition in 2018, and licensing both globally and regionally. Angus departed Celgene to serve as CEO of Dementia Discovery Fund (DDF), inspired by their mission to invest in and build the early-stage biotech companies most likely to develop transformative treatments for neurodegenerative diseases, to the benefit of the millions of people suffering from this health crisis of the 21st century that has longed lacked effective treatments. Dr. Grant received his undergraduate degree from the University of Richmond and a Ph.D. in anatomy and immunology from the Medical College of Virginia, and he completed his postdoctoral training at the National Cancer Institute. Dr. Grant currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. He is a published scientist, co-authoring more than 15 articles in peer-reviewed scientific journals. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative medicines research and operations supporting our growing portfolio of innovative medicines and biopharmaceutical products. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to our business and operations in general, including our ability to attract, hire and retain highly skilled key personnel, our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to execute on our Pivot to Growth strategy; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2023 and in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.